COMPANY:

Genecentric

"GeneCentric...today announced the launch of its EXpressCTcm (Expression Signatures Through Circulating Tumor Signals) liquid biopsy platform that allows the value of tissue RNA expression and epigenomics to be realized in liquid biopsy. EXpressCT expands the application of the company’s pipeline of RNA-based gene expression signatures and diagnostic tests to cell-free DNA (cfDNA) liquid biopsy samples, including blood and urine."

P=NA | N=NA | "GeneCentric Therapeutics...announced today that results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancER) study were published in Clinical Cancer Research....Although many HR-NMIBC patients respond to BCG treatment, 50-70% have a recurrence, and up to 20% progress to muscle-invasive bladder cancer (MIBC) or locally advanced/metastatic disease. Alternative therapies including FGFR-targeting agents are being investigated....The FGFR alteration frequency (i.e., FGFR ALT (+)) in HR-NMIBC tumors was 31%. The frequency of FGFR-activated tumors using the FGFR-PRS was more than twice as high as FGFR ALT+ at 75%."

"GeneCentric Therapeutics...announced today that the American Medical Association (AMA) has granted a PLA code for the PurIST pancreatic cancer test.... The PurIST test classifies the tumors of patients with unresectable stage III or stage IV pancreatic ductal adenocarcinoma (PDAC) as either a basal or classical subtype and can help guide first-line therapy."

"GeneCentric Therapeutics...today announced upcoming presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 31st to June 4th. Presentations include new clinical validation results for a novel signature identifying patients with head and neck squamous cell carcinoma (HNSCC) that may benefit from treatment beyond typical surgical resection....In addition, GeneCentric will present updated findings from its development of a novel RNA-based immune checkpoint inhibition predictive response signature (ICI-PRS) that optimizes the selection of patients with a primary diagnosis of urothelial cancer who are potential candidates for anti-PD-(L)1 inhibition treatment."

"GeneCentric Therapeutics...announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10. Presentations will include a poster describing a new colorectal cancer predictive response signature (MSS-PRS) that selects tumors not identified with conventional MSI testing but have molecular characteristics consistent with microsatellite instability, making them a potential target for immune checkpoint inhibition. A second poster presentation describes ongoing clinical validation for PurISTSM, a novel RNA-expression test developed in collaboration with Tempus. PurIST identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) that are likely to experience longer overall survival with standard of care FOLFIRINOX than patients with the basal subtype of PDAC."

"GeneCentric Therapeutics...today announced upcoming presentations at the Precision Medicine World Conference (PMWC) in Santa Clara, California from January 24-26 and the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which will be held January 25-27 in San Francisco, California....'We look forward to sharing data about the ongoing discovery and development of our novel RNA-based signatures and tests at the PMWC and ASCO GU meetings,'..."

"GeneCentric Therapeutics...announced today the publication of initial results from the ongoing Piedmont study using real-world data in lung cancer to develop its novel RNA-based Antifolate Predictive Response Signature (AF-PRS), which is being co-developed as a clinical diagnostic test with Labcorp. The retrospective analysis was published in the peer-reviewed journal Clinical Cancer Research....The initial analysis focused on non-squamous non-small cell lung cancer (NS-NSCLC) patients treated with standard-of-care (SOC) pemetrexed/platinum doublet chemotherapy. Results showed over half (53%) of patients that were AF-PRS(+) had extended progression-free survival (PFS) versus those who were AF-PRS(-) (16.6 months vs. 6.6 months; P=0.025). Furthermore, the significant PFS difference was even more pronounced between AF-PRS(+) and AF-PRS(-) patients who were non-metastatic (36.2 months vs. 9.3 months; P=0.03)."

"GeneCentric Therapeutics...announced today that its PurIST^SM test is now commercially available through Tempus for clinical use. PurIST is a novel RNA-expression test that identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) who are likely to experience longer overall survival (OS) with standard-of-care (SOC) FOLFIRINOX than patients with the basal subtype of PDAC."

"GeneCentric Therapeutics...announced today the initiation of its Alamance study, a multi-center bladder cancer study conducted in collaboration with investigators at Memorial Sloan Kettering Cancer Center and the University of Wisconsin – Madison Carbone Cancer Center....In this prospectively designed real-world evidence study, clinical response data and existing tumor samples are being collected from a multi-center cohort of approximately 250 patients with locally advanced or metastatic urothelial (bladder) cancer treated with FGFR-targeted therapy (e.g., erdafitinib) or other standards of care (e.g., anti-PD-(L)1 or platinum-based chemotherapy)."

"GeneCentric Therapeutic...announced today the poster presentation of further clinical validation data for PurIST^SM, a novel RNA-expression test, in collaboration with Tempus. PurIST identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) that are likely to experience longer overall survival (OS) with standard of care (SOC) FOLFIRINOX than patients with the basal subtype of PDAC. The presentation will be made at the 8th AACR Special Conference on Pancreatic Cancer in Boston, Massachusetts, which runs from September 13-16, 2022."